A Study To Investigate The Drug-Drug Interaction Potential Of Rifampin OnThe Investigational Agent Palbociclib (PD-0332991)

Completed · Phase 1

Conditions studied: Healthy

In brief

This study will compare the plasma pharmacokinetics of a single 125mg oral dose of palbociclib in the presence and absence of rifampin-mediated enzyme induction in a fixed-sequence two-period study.

Key facts

Study ID

NCT01953731

Run by

Pfizer

People needed

15

Starts

2013-10-01

Expected to finish

2014-01-01

Last updated by the study team

2014-01-20

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy males or females of non-childbearing potential
• body mass index between 17.5-30.5 kg/m2 with a total body weight greater than 50kg

You may not qualify if…

• Evidence or history of any clinically significant physiologic, psychological, or medical conditions
• a positive drug screen or alcohol breath test
• a baseline ECG demonstrating a QTc>450msecs or a QRS interval >120msecs

Where it is running

• Pfizer Investigational Site — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.